[Relationship between the levels of KAI1/CD82 and CD44 and the clinicopathological features of non-small cell lung cancer].
OBJECTIVE
To observe the relationship between levels of KAI1/CD82 and CD44 in lung carcinomas and their clinicopathological features, in association with the results of metastasis.


METHODS
The expressions of KAI1/CD82 and CD44 in 45 patients with lung cancer were detected by flow-cytometry. Tissue samples 3 cm (control group 1) and 5 cm (control group 2) from the cancerous lesions and benign lesions from 30 patients (control group 3) were also studied, and the results were compared.


RESULTS
The expression level of KAI1/CD82 protein in lung cancer was lower than that in other three groups (P < 0.01), while the expression level of CD44 was higher than that in other three groups (P < 0.01). The expression level of KAI1/CD82 in control group 1 was also lower than that in control group 2 and benign lesion group (P < 0.05). The expression level of CD44 was higher than that in control group 2 and benign lesion group (P < 0.05). There was no significant difference between the expression level of CD44 and KAI1/CD82 in control group 2 and benign lesion group (P > 0.05). The expression level of KAI1/CD82 and CD44 were closely correlated with clinical staging, pathological differentiation and lymph node metastasis (P < 0.01), but their expressions were not correlated with sex, age, tumor size and pathological type (P > 0.05). Statistic difference was found between KAI1/CD82 and CD44 in primary lesions and metastatic lesions (P < 0.01). There was an inversely correlation between the expression of CD44 and KAI1/CD82 in clinical staging and lymph node metastasis (P < 0.01).


CONCLUSIONS
KAI1/CD82 and CD44 may play an important regulating role in the genesis, development and metastasis of lung cancer, and they may be used as potential markers for tumor metastasis.
Chen
Qing-yong
QY
Department of Respiratory Medicine, 117th Hospital of People's Liberation Army, Hangzhou 310013, China.
Lin
Xian-ming
XM
Zhou
Jian-ying
JY
An
Zhou
Z
Yang
Ling
L
Jiang
Zhong-yong
ZY
D000328:Adult; D000368:Aged; D015703:Antigens, CD; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry* / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis*; D051861:Kangai-1 Protein; D008175:Lung Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis* / Q000235:genetics; D008875:Middle Aged; D009367:Neoplasm Staging; D011518:Proto-Oncogene Proteins
D015703:Antigens, CD; C497688:CD82 protein, human; D018960:Hyaluronan Receptors; D051861:Kangai-1 Protein; D008562:Membrane Glycoproteins; D011518:Proto-Oncogene Proteins